Skip to content

Censo Biotechnologies (Axol Bioscience)

Sector:
Healthcare Services
Invested in:
Calculus EIS, Calculus VCT

Axol and CENSO supply high quality adult human cells, especially live human neurons, created by stem cell technology, to many of the world’s biggest and best-known pharma companies and research institutions.

Axol Bioscience merged with Censo Biotechnologies in March 2021.

These induced pluripotent stem cells (iPSCs), which are derived from healthy adult patients of specific disease backgrounds, are used for medical research, disease modelling and drug development.

The merger of Axol and CENSO creates a global leader in the research and production of iPSC derived cell lines and custom service work. With customers in the US, Europe and Asia, the combined entity will have manufacturing sites in Cambridge and Edinburgh, increasing production capacity to ensure growing demand can continue to be met with short lead times and high quality output.

Rationale

Funds from Calculus Capital will enable growth of the combined business and acquisition of talent in order to meet customer demand.

Latest News

Calculus Capital invests in Axol Bioscience following merger with Censo Biotechnologies

Biotech sector-leaders combine tools, talent, and technologies to drive life science discovery forward Merger accompanied by £3.8million ($5.3m USD) investment across existing shareholders and new investors, which will be used to fund recruitment and growth of the business Axol Bioscience Ltd, an established provider of stem cells produced from reprogrammed human blood and tissue cells, … Continued

Spotlight On: Axol Bioscience

As part of our ‘Spotlight On’ series, we focus on Axol Bioscience, a company who provides human cell culture systems for medical research, disease modelling and drug development. Axol Bioscience supplies high quality human cells, both healthy and diseased, to many of the world’s biggest pharmaceutical companies and best known research institutions. Axol generates stem … Continued

Axol Bioscience introduces Human iPSC-derived Atrial Cardiomyocytes

Calculus Capital portfolio company, Axol Bioscience Ltd., has launched their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease. As a human cell culture specialist they already provide custom services for disease modelling and drug discovery markets.  Generated from the same donor as Axol’s highly validated … Continued

Calculus Capital invests £2.5m in Axol Bioscience

Calculus Capital invests £2.5m in Axol Bioscience Private equity firm Calculus Capital, a leading EIS and VCT investor, has completed its third deal in two weeks, investing £2.5m in Cambridge-based Axol Bioscience (Axol), a provider of stem cells produced from reprogrammed human blood and tissue cells. Axol supplies high quality human cells especially live human … Continued